When it comes to exports, Celltrion Healthcare leads the way among Republic of Korea pharmaceuticals producers. The company's biosimilars are the leading exports.
The Republic of Korea’s might as a pharmaceutical producer continues to grow. The country’s Ministry of Food and Drug Safety reported a 62.5% surge in exports of medicine in 2020 to $8.7 billion, according to the Korea Biomedical Review.
The top 3 drugs among exported Korean pharmaceutical products were all biosimilars produced by Celltrion: Remsima (infliximab), $473 million; Herzuma (trastuzumab), $85.8 million; Truxima (rituximab), $65.5 million. These agents are used in the treatment of rheumatoid arthritis, breast and gastric cancer, and arthritis and lymphoma, respectively.
The top 3 international importers of Korean drugs were Germany ($1.85 billion), United States ($780 million), and Turkey ($589 million), according to the Review.
Eight biosimilar products produced in Korea were among the top 20 drugs exported in 2020.
The top 10 companies producing drugs in Korea in 2020 were Celltrion, whose output surged 149.2%, Hanmi Pharmaceutical, Chong Kun Dang, GC Pharma, inno.N, Daewoong Pharmaceutical, Yuhan, LG Chem, Dong-A ST, and JW Pharmaceutical. Almost all of these companies are involved in the production or distribution of biosimilars.
Hanmi has a heavy emphasis on insulin products. The company produced $992 million in medicines in 2020.
Celltrion’s Push Into Latin America
Celltrion said Tuesday, August 3, 2021, that it has contracted to market Herzuma and Truxima in Brazil following a successful bid to Brazil’s ministry of health. The company said it would supply trastuzumab to the public market, which accounts for 80% of trastuzumab demand in the country. Celltrion said that so far this year, it has won 8 state bids for supplying rituximab, including one in Sao Paulo, which it said is one of the largest state contracts.
“There is a great demand to substitute expensive original pharmaceuticals with biosimilar drugs with proven safety and efficacy to reduce health care costs in Central and South America,” said HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion. “We are excited to win one of the most important bids in Brazil for 2 consecutive years and will continue to expand our presence in the Central and Southern American market with our anticancer biosimilar products.”
In March 2021, Celltrion began direct sales of infliximab biosimilar in Colombia and is beginning to market rituximab and trastuzumab biosimilars there this summer. The company also plans to sell biosimilars in Peru and Chile starting in the third quarter of this year.
Click here for further reading on Celltrion's growing investment in biopharmaceutical production.
Click here for an article about Republic of Korea's 2019 pharmaceutical production and exports.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.